Brief: ARCH BIOPARTNERS INITIATES MANUFACTURING PROCESS FOR METABLOK
10/10/2017 11:30
Oct 10 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS INITIATES MANUFACTURING PROCESS FOR
METABLOK
* ARCH BIOPARTNERS - ENGAGED CSBIO TO BEGIN MANUFACTURING
PROCESS FOR METABLOK DRUG CANDIDATE FOR TREATING INFLAMMATION,
CANCER METASTASIS AND SEPSIS
* ARCH BIOPARTNERS INC - ARCH IS PLANNING A PHASE I HUMAN
TRIAL TO EVALUATE METABLOK'S SAFETY AND PHARMACOKINETIC PROFILE
* ARCH BIOPARTNERS INC- INVESTIGATIONAL NEW DRUG (IND)
APPLICATION TO U.S. FDA IS CURRENTLY BEING PREPARED BY METABLOK
TEAM FOR SUBMISSION IN 2018
Source text for Eikon: ID:nMKWTkkQHa
Further company coverage: ARCH.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide